Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
about
Gastric biomarkers: a global reviewCorrelation of cadherin-17 protein expression with clinicopathological features and prognosis of patients with sporadic gastric cancerMolecular classification of gastric cancer: Towards a pathway-driven targeted therapyAssociation between Polymorphisms in Vascular Endothelial Growth Factor Gene and Response to Chemotherapies in Colorectal Cancer: A Meta-AnalysisCIViC databaseThe AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere.Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers.Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform.Influences of laparoscopic-assisted gastrectomy and open gastrectomy on serum interleukin-6 levels in patients with gastric cancer among Asian populations: a systematic reviewSuccessful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpressionPhosphorylated Mammalian Target of Rapamycin p-mTOR Is a Favorable Prognostic Factor than mTOR in Gastric CancerPulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis.Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.To Excavate Biomarkers Predictive of the Response for Capecitabine plus RAD001 through Nanostring-Based Multigene Assay in Advanced Gastric Cancer Patients.Targeted therapy for gastric cancer.Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms.HER2 therapies and gastric cancer: a step forward.Biomarkers for gastric cancer: prognostic, predictive or targets of therapy?Predictive biomarker candidates for the response of gastric cancer to targeted and cytotoxic agents.PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer.Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patientsNovel biomarkers for the identification and targeted therapy of gastric cancer.Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions.Evolving treatments for advanced gastric cancer: appraisal of the survival trend.Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors.Phase II trial of capecitabine and everolimus (RAD001) combination in refractory gastric cancer patients.Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors.Treatment-related fatigue with everolimus and temsirolimus in patients with cancer-a meta-analysis of clinical trials.PIK3CA mutations are associated with increased tumor aggressiveness and Akt activation in gastric cancer.Angiogenesis inhibitors in early development for gastric cancer.Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer.Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer.Effect of Target Therapy on the Content of Transcription and Growth Factors, Protein Kinase TOR, and Activity of Intracellular Proteases in Patients with Metastatic Renal Cell Carcinoma.Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.
P2860
Q26741859-FAB92FAC-EC7C-42B9-B43C-54FD3227F019Q26783991-4593FB07-D255-4B6A-B076-68D4C09E61AAQ26798420-34B01E32-26ED-4073-9DCA-9C20C469CB98Q26862559-2A451642-CC3E-4949-87CA-07EC1E201000Q27612411-E3213E1C-9AE9-498D-8577-DC496F7C1663Q27852562-585ACF1B-3737-44B0-AC75-DE5D1B151904Q28079596-4F95AF08-C832-4178-BE03-7FE798777ECEQ33422778-25EAE53C-F983-4D39-9099-11BF05EBF4CFQ33903687-0F4C1353-0104-400B-858F-D091EAA113BCQ35583924-6EEC79AF-0FCE-4669-9CC3-C0A78AACDD53Q35606679-D046E670-0B42-4110-9F96-93A9AE93A17AQ36231547-D8E13923-4C69-489C-A8F0-6EE3EDDE75E6Q36553511-6FA84498-3C17-4012-8E27-09E5ADD173F2Q36963020-994A0691-525F-48CA-AE98-A5D4C1D48878Q37514034-8FE41943-4A1B-42C1-9F5B-D2AA70AC886AQ38007119-3D57DE4F-0475-4AD0-A51D-B3EFF85BCEE9Q38123696-E42E2344-E604-47CA-9B3E-4D63CC51FB37Q38151672-F03B958C-E8D3-4A57-9E91-302532FA5BEFQ38184380-E839036F-7655-49EE-85B3-511D71E2F0F5Q38188598-E229F105-6B6F-41FF-890E-9F9F346EFE9AQ38236320-BCDF0B4C-B77C-44A1-8489-AF7CA36FD631Q38241766-62AF98BC-927D-4AB7-881C-3CEF1852A3DBQ38374414-F9B992C3-2606-452E-A78A-81CBB58CBE71Q38556435-18B3FA47-15CE-431A-A947-68C55F155EFEQ38653626-F291466A-8FAF-42AF-BB4F-CD7F1F82FC9FQ38823374-328580A9-8E25-4EED-A8A0-D6678B008433Q38907631-5C8CEFA2-E8FA-4A54-A35D-1944A679CEABQ38912656-67D2668C-C21F-4A73-BF1D-405977D97F7CQ39733256-969EB9BB-21CD-4622-B276-7AD4860DF5C3Q44216566-08501824-C223-4D66-8D5C-9D0E84C365F4Q45890813-FA6EF3C8-79E3-4D9E-966F-E71E01E94EA1Q46909057-0A931C50-4140-45E2-950F-677F2F4A8E92Q47157362-9D78F5C7-BFEA-4E6C-9817-912D18EEA64BQ47996955-5580DAE4-3915-455B-BEC7-7F7A8EBDFBE8Q48379063-D481F4CD-87EE-447B-A448-04ADC448C8DDQ52661828-BC08B3C3-E9E6-4A4E-8FDD-7DA4BBBE382FQ53067336-CB3644CA-371F-49D6-B4DA-2C8E4727A491Q55022904-C8FC03A9-5938-447E-9AB9-B096ACC73216Q55322223-5A10B372-1E46-49AF-88AF-041106E4DFA8
P2860
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phase II study of everolimus w ...... fluoropyrimidine and platinum
@ast
Phase II study of everolimus w ...... fluoropyrimidine and platinum
@en
Phase II study of everolimus w ...... fluoropyrimidine and platinum.
@nl
type
label
Phase II study of everolimus w ...... fluoropyrimidine and platinum
@ast
Phase II study of everolimus w ...... fluoropyrimidine and platinum
@en
Phase II study of everolimus w ...... fluoropyrimidine and platinum.
@nl
altLabel
Phase II study of everolimus w ...... fluoropyrimidine and platinum
@en
prefLabel
Phase II study of everolimus w ...... fluoropyrimidine and platinum
@ast
Phase II study of everolimus w ...... fluoropyrimidine and platinum
@en
Phase II study of everolimus w ...... fluoropyrimidine and platinum.
@nl
P2093
P2860
P921
P356
P1476
Phase II study of everolimus w ...... fluoropyrimidine and platinum
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.2012.47
P407
P577
2012-03-13T00:00:00Z
P5875
P6179
1030389345